Core Points - MapLight Therapeutics, Inc. has successfully closed its initial public offering (IPO) of 16,962,500 shares at a price of $17.00 per share, including the full exercise of underwriters' option for an additional 2,212,500 shares [1][3] - The company also completed a concurrent private placement of 476,707 shares at the IPO price to affiliates of Goldman Sachs, which was not registered under the Securities Act [2][3] - The total gross proceeds from both the IPO and private placement amounted to $296.3 million before deducting underwriting discounts and expenses [3] Company Overview - MapLight Therapeutics is a clinical-stage biopharmaceutical company focused on treating patients with central nervous system disorders [6] - The company was founded by leaders in psychiatry and neuroscience to develop circuit-specific pharmacotherapies [6] - Its lead product candidate, ML-007C-MA, is currently in Phase 2 clinical trials for schizophrenia and Alzheimer's disease psychosis [6]
MapLight Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares